3 results
The primary hypothesis of this study is that ibrutinib compared with temsirolimus significantly prolongs PFS in subjects with relapsed or refractory MCL who have received at least 1 prior rituximab-containing chemotherapy regimen.
To compare one dose of the short acting tropicamide combined with one dose of the longer acting cyclopentolate (c+t) with a double dose of the longer acting cyclopentolate (c+c). To develop a cycloplegics protocol that garantees optimal refractieve…
1. To determine whether AFO stiffness can be optimized for individual patients in terms of minimizing the energy cost of walking. 2. To asses whether the optimal AFO in terms of energy cost of walking matches the AFO at which the most energy can be…